The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Poster
Efficacy of brentuximab vedotin combination treatment in patients with relapsed or refractory diffuse large b-cell lymphoma with CD30 <1% expression
Nowakowski G, King R, Kearney D, Bartlett N, Kim JA, Fleury I, Mollica L, Portell C, Yasenchak C, Fenton K, Hale C, Hubbard D, Lu H, Patterson M, Fanale M, Rustia E, Hahn U
Poster
Frontline brentuximab vedotin and CHP in patients with peripheral T-cell lymphoma with <10% CD30 expression: primary analysis results from the phase
Iyer S, Jagadeesh D, Domingo Domenech E, Benedetti F, Rodriguez Izquierdo A, Bouabdallah K, Vitolo U, Illidge TM, Liu J, Shaikh E, Horwitz S
Brentuximab vedotin | June 1, 2025 | ASCO, ASCO 2025
C5691004 | NCT04569032
Presentation
Phase 2 open-label study of brentuximab vedotin + pembrolizumab in patients with treatment-naive metastatic head and neck squamous cell carcinoma
Rodriguez C, Lee S, Watson G, Gillespe-Twardy A, Laux D, Ward P, Yorio J, Abughanimeh O, Beck TJ., Kim K, Lu H, Berndt J, Chaney M, Shaikh E, Alesi E
Poster
Outcomes by Refractory Status and Prior Therapies Received in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Hahn U, Bartlett N, Kim J, Bouabdallah KK, Forward N, Chen T-Y, Camus V, Wang MC, Carassou P, Derenzini E, Chang H, Offner F, Ghesquieres H, Nowakowski G, Yasenchak C, Patterson M, Ho L, Rustia E, Fanale M, Fenton K, Portell C
Poster
Outcomes in Older Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) from the ECHELON-3 Study
Bartlett N, Kim J, Hahn U, Fleury K, Laribi K, Bergua JM, Portell C, Boutin M, Sanchez Gonzalez B, Lam S, Oh SY, Joergensen JM, Do YR, Ghesquieres H, Nowakowski G, Yasenchak C, Patterson M, Ho L, Rustia E, Fanale M, Fenton K, Ribrag V
Poster
Durability of Complete Responses in Patients from the ECHELON-3 Study
Yasenchak CA, Bartlett N, Kim J, Hahn U, Portell C, Zaja F, Zenz T, Forsyth C, Kim JS, Cho S-G, Kwak J-Y, Wang H-Y, Ghesquieres H, Nowakowski G, Patterson M, Ho L, Rustia E, Fanale M, Fenton K, Stenner F